Hadassah

Hadassah-Developed Imaging Agent to Begin Clinical Trials with Multi-million Euro Grant

Monday, Feb 8 2016

Prof. Eyal Mishani, head of Research and Development at the Hadassah Medical Center.

The Hadassah Medical Organization has been awarded a €3.69 million ($4 million) grant from the European Union (EU) to begin clinical trials with its Hadassah-developed innovative radioactive imaging substance that may reduce the need for exploratory cardiac catheterizations.

The invention of this imaging agent heralds a new stage in the diagnosis of cardiovascular  disease, the leading cause of death in the world. Currently, millions of diagnostic heart catheterizations are performed each year in the United States; less than half of them reveal heart problems that require further intervention.

Currently, Hadassah is the only hospital in the world to have this PET/CT cardiac imaging "tracer,” pioneered by Prof. Eyal Mishani, head of Research and Development at Hadassah and its Cyclotron and Radiochemistry Unit, along with his team in the Radiochemistry Unit and Hadassah Cardiologist Prof. Chaim Dannenberg. With this imaging tracer, the cardiologist can more specifically diagnose heart blockages. As Prof. Mishani explains: When this tracer is injected into the patient, it accumulates in the heart, enabling the physician to measure blood flow in absolute values and pinpoint the location of problems.”

The grant is part of the EU's Horizon 2020 program and the Hadassah tracer was one of three funded projects from among 110 top applicants in the health field. Prof. Mishani notes: "The grant is an important recognition by the European Commission for our work in translational medicine, our ability to move from the laboratory to the bedside."

The tracer was exclusively licensed by Hadasit, Hadassah’s technology transfer company, in 2013 to the grant applicant, Synektik S.A., a Poland-based leading provider of innovative solutions for medical imaging in Europe. This first-in-human clinical trial is slated to begin this year. Hadassah already has the approval of both its Helsinki Ethics Committee and Israel's Ministry of Health to launch the trial. 

The cyclotron, a piece of equipment that requires a unique infrastructure, including a bunker to shield it, can synthesize radioactive atoms that are incorporated into biological compounds to create imaging agents which are then used in conjunction with PET and CT scanning. Patients typically receive an injection of a small quantity of the tracer and then a special camera of the PET scanner detects how the body processes the tracer as it illuminates the heart. In this way, specific heart blockages in specific locations are highlighted.

While few hospitals have a cyclotron, Hadassah has two. The first was donated in 1994; the second, in 2010.

Comments

From: Karen Greenberg on February 13, 2016
I am an RN in the USA who was just D\C'd home from the Hospital post cath for angina & SOB. Besides your wonderful nonevasive testing, what Tx's does Hadassah have for CAD from IDDM? My thanks, Karen
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Jan 13 2017

Saving Children in the Nick of Time at Hadassah

When a four-year-old, blue and critically ill, was rushed into the pediatric emergency room at Hadassah Hospital Mount Scopus, Dr. David Rekhtman, head of the ER, and his team deciphered that the child had somehow consumed methadone.

READ MORE ›
alt_text

Friday, Jan 13 2017

Peace in Sight: An Israeli, Palestinian, and Hadassah Australia Collaboration

St. John of Jerusalem Eye Hospital, in collaboration with Hadassah Medical Center, has received a €500,000 grant from the European Union to establish a genetic research unit to serve the Palestinian communities.

READ MORE ›
alt_text

Friday, Jan 13 2017

A Second Chance at Life, Thanks to Hadassah’s Heart Institute

A resident of a rural settlement called Dishon, established by Libyan Jewish immigrants in 1953, Eyal Amar, age 47, was rather young to suffer a devastating heart attack. Nevertheless, he did, but thanks to the courage and skill of the specialists at the Hadassah Medical Organization’s Heart Institute and their complex protocol to redesign his heavily damaged heart, Eyal is able to walk and breathe again.

READ MORE ›
alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More